Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy

Annals of Noninvasive Electrocardiology

Volumn 17, Issue 1, 2012, Pages 14-21

  George, Jenie ^a   Barsheshet, Alon ^a   Moss, Arthur J ^a   Martin, David ^b   Ouellet, Gregory ^a   McNitt, Scott ^a   Goldenberg, Ilan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

cardiac resynchronization therapy; cardiomyopathy; diabetes mellitus; heart failure

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEFIBRILLATOR; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; RISK REDUCTION; THERAPY EFFECT;

ADULT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHIES; DEFIBRILLATORS, IMPLANTABLE; DIABETIC ANGIOPATHIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 84856344471     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2011.00476.x     Document Type: Article

References (21)

1. Singh S, Dhingra S, Ramdath DD, et al,. Risk factors preceding Type 2 diabetes and cardiomyopathy. J Cardiovasc Transl Res 2010; 3: 580-596.
2. Boudina S, Abel ED,. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-3223. (Pubitemid 47012236)
3. Boudina S, Abel ED,. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11 (1): 31-39.
4. Das SR, Drazner MH, Yancy CW, et al,. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: A retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J 2004; 148 (5): 883-888.
5. Martin DT, McNitt S, Nesto RW, et al,. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). Circ Heart Fail 2011; 4: 332-338.
6. Moss AJ, Hall WJ, Cannom DS, et al,. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361 (14): 1329-1338.
7. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation 2008; 117: e350-e408.
8. Lang RM, Bierig M, Devereux RB, et al,. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiography 2005; 18: 1440-1463. (Pubitemid 41821197)
9. Iltis I, Kober F, Dalmasso C, et al,. Noninvasive characterization of myocardial blood flow in diabetic, hypertensive, and diabetic-hypertensive rats using spin-labeling MRI. Microcirculation 2005; 12: 607-614. (Pubitemid 43023804)
10. Fein FS,. Diabetic cardiomyopathy. Diabetes Care 1990; 13: 1169-1179. (Pubitemid 20365922)
11. Rubler S, Dlugash J, Yuceoglu YZ, et al,. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
12. Zhi YF, Johannes BP, Thomas HM,. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004 25: 543-567. (Pubitemid 39096070)
13. Kannel WB, McGee DL,. Diabetes and cardiovascular disease: The Framingham study. JAMA 1979; 241: 2035-2038. (Pubitemid 9228506)
14. Bella JN, Devereux RB, Roman MJ, et al,. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 2001; 87: 1260-1265. (Pubitemid 32493866)
15. Galderisi M, Anderson KM, Wilson PW, et al,. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68: 85-89.
16. Verhaert D, Grimm RA, Puntawangkoon C, et al,. Long-term reverse remodeling with cardiac resynchronization therapy: Results of extended echocardiographic follow-up. J Am Coll Cardiol 2010; 55: 1788-1795.
17. Lilli A, Ricciardi G, Porciani MC, et al,. Cardiac resynchronization therapy: Gender related differences in left ventricular reverse remodeling. Pacing Clin Electrophysiol 2007; 30: 1349-1355. (Pubitemid 350043826)
18. Cleland JG, Daubert JC, Erdmann E, et al,. Cardiac Resynchronization- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med 2005; 352: 1539-1549. (Pubitemid 40517094)
19. St John Sutton MG, Plappert T, Abraham WT, et al,. Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107: 1985-1990. (Pubitemid 36506071)
20. Adelstein EC, Saba S,. Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. Am J Cardiol 2009; 103: 238-242.
21. Wokhlu A, Rea RF, Asirvatham SJ, et al,. Upgrade and de novo cardiac resynchronization therapy: Impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm 2009; 6: 1439-1447.